Cambridge Cognition appoints Pfizer's Keir CEO
This article was originally published in Scrip
UK developer of computerised neuropsychological tests for the pharmaceutical industry and research institutions, Cambridge Cognition, has appointed Ruth Keir CEO. Ms Keir was previously head of global strategic alliances at Pfizer, and was actively involved in the implementation of the Innovative Medicines Initiative. Cambridge Cognition has also hired Professor Wim Riedel, head of experimental psychopharmacology at Maastricht University in the Netherlands, as vice-president of science. Professor Riedel was previously global head of neuropsychology at GlaxoSmithKline.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.